Evidence map›Paper›PMID 30680775›Full record

Trial reportAmerican journal of hematology2019

Heritability of fetal hemoglobin, white cell count, and other clinical traits from a sickle cell disease family cohort.

Erik L Bao, Caleb A Lareau, Carlo Brugnara, Isabel R Fulcher, Caroline Barau, Stephane Moutereau, Anoosha Habibi, Bouchra Badaoui, Jugurtha Berkenou, Pablo Bartolucci and 4 more

Registry-linked trialOpen access · bronzeAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in American journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06019208 (Genomics and Personalized Medicine for All Though Artificial Intelligence in Haematological Diseases), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06019208 unknown statusnot on this mapstarted 2021, after this paper: background citation

Genomics and Personalized Medicine for All Though Artificial Intelligence in Haematological Diseases

TypeobservationalSponsorHospital Universitari Vall d'Hebron Research InstituteRan2021 to 2024Enrolled1,000ConditionsSickle Cell Disorders
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Improved Titer and Gene Transfer by Lentiviral Vectors Using Novel, Small β-Globin Locus Control Region Elements.Molecular therapy : the journal of the American Society of Gene Therapy · 2020
    Article
  4. Review
  5. Sickle cell disease in the era of precision medicine: looking to the future.Expert review of precision medicine and drug development · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Erik L BaoDivision of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-6074-6766
Caleb A LareauDivision of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-4179-4807
Carlo BrugnaraDepartment of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-8192-8713
Isabel R FulcherDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Caroline BarauPlateforme de Ressources Biologiques, Hopital Universitaire Henri Mondor, Créteil, France.
Stephane MoutereauService de Biochimie, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Créteil, France.
Anoosha HabibiRed Cell Genetic Disease Unit, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est IMRB - U955 - Equipe n°2, Créteil, France.
Bouchra BadaouiDépartement d'Hématologie et d'Immunologie Biologiques, Assistance Publique-Hôpitaux de Paris, Hôpitaux universitaires Henri Mondor, Créteil, France.
Jugurtha BerkenouRed Cell Genetic Disease Unit, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est IMRB - U955 - Equipe n°2, Créteil, France.
Pablo BartolucciRed Cell Genetic Disease Unit, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est IMRB - U955 - Equipe n°2, Créteil, France.
Frédéric GalactérosRed Cell Genetic Disease Unit, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est IMRB - U955 - Equipe n°2, Créteil, France.
Orah S PlattDepartment of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Michael MahaneySouth Texas Diabetes and Obesity Institute, School of Medicine, The University of Texas Rio Grande Valley, Brownsville, Texas.
Vijay G SankaranDivision of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-0044-443X
Assistance Publique – Hôpitaux de Paris · FRBroad Institute · USBoston Children's Hospital · USHarvard University · USHôpitaux Universitaires Henri-Mondor · FRThe University of Texas Rio Grande Valley · US

Funding

Translational and clinical studies targeting y-globin modulationU01HL117720 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI SANKARAN, VIJAY GANESH · 2013 to 2017
$7.4M
Systematic Genetic Dissection of Human ErythropoiesisR01DK103794 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI Vijay Ganesh Sankaran · 2014 to 2026
$5.9M
GENETIC MODIFIERS OF SEVERITY IN SICKLE CELL ANEMIAR01HL068922 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI PLATT, ORAH S · 2001 to 2005
$3.6M
Identifying Genome-wide Association Study-Nominated Regulators of ErythropoiesisR33HL120791 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI SANKARAN, VIJAY GANESH · 2016 to 2018
$1.7M
Howard Hughes Medical Institute Medical Research Fellows ProgramNHLBI NIH HHS R01 HL068922NHLBI NIH HHS R33 HL120791NHLBI NIH HHS U01 HL117720NIDDK NIH HHS R01 DK103794
6 · The paper itself

Abstract

Sickle cell disease (SCD) is the most common monogenic disorder in the world. Notably, there is extensive clinical heterogeneity in SCD that cannot be fully accounted for by known factors, and in particular, the extent to which the phenotypic diversity of SCD can be explained by genetic variation has not been reliably quantified. Here, in a family-based cohort of 449 patients with SCD and 755 relatives, we first show that 5 known modifiers affect 11 adverse outcomes in SCD to varying degrees. We then utilize a restricted maximum likelihood procedure to estimate the heritability of 20 hematologic traits, including fetal hemoglobin (HbF) and white blood cell count (WBC), in the clinically relevant context of inheritance from healthy carriers to SCD patients. We report novel estimations of heritability for HbF at 31.6% (±5.4%) and WBC at 41.2% (±6.8%) in our cohort. Finally, we demonstrate shared genetic bases between HbF, WBC, and other hematologic traits, but surprisingly little overlap between HbF and WBC themselves. In total, our analyses show that HbF and WBC have significant heritable components among individuals with SCD and their relatives, demonstrating the value of using family-based studies to better understand modifiers of SCD.

Indexed as

FamilyQuantitative Trait, HeritableAdultAnemia, Sickle CellCohort StudiesFemaleFetal HemoglobinHumansLeukocyte CountMaleFetal Hemoglobin

Identifiers

PMID30680775
PMCPMC6449202
OpenAlexW2914210908

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.